You just read:

DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting

News provided by

DelMar Pharmaceuticals, Inc.

Jun 03, 2019, 08:45 ET